ArticleJCI insight2018
Transcranial optical imaging reveals a pathway for optimizing the delivery of immunotherapeutics to the brain.
Article in JCI insight, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Pooled it
- Novel Therapeutic Insights Into Alzheimer's Disease: Glymphatic System and Meningeal Lymphatic Vessels.Aging cell · 2026Review
- Efficient targeting of human glial progenitor cells in vivo with engineered AAV vectors and glymphatic delivery.Nature biotechnology · 2026Article
- Reconstructing cerebral lymphatic clearance: an emerging target in the Alzheimer's disease therapeutic pipeline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Robust MR-AIV: A Systematic Study of Robustness Improvement and Sensitivity Analysis of MR-AIV.bioRxiv : the preprint server for biology · 2026Article
- MR-AIV revealsbioRxiv : the preprint server for biology · 2025Article
- Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials.Translational neurodegeneration · 2025Review
- Perivascular interactions and tissue properties modulate directional glymphatic transport in the brain.Fluids and barriers of the CNS · 2025Article
- Blood osmolytes such as sugar can drive brain fluid flows in a poroelastic model.Scientific reports · 2024Article
- Enhancing glymphatic fluid transport by pan-adrenergic inhibition suppresses epileptogenesis in male mice.Nature communications · 2024Article
- Astrocytes sense glymphatic-level shear stress through the interaction of sphingosine-1-phosphate with Piezo1.iScience · 2024Article
- Role of the Glymphatic System in Alzheimer's Disease and Treatment Approaches: A Narrative Review.Cureus · 2024Review
- Changes in cardiac-driven perivascular fluid movement around the MCA in a pharmacological model of acute hypertension detected with non-invasive MRI.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024Article
- Transient but not chronic hyperglycemia accelerates ocular glymphatic transport.Fluids and barriers of the CNS · 2024Article
- Therapeutic approaches to CNS diseases via the meningeal lymphatic and glymphatic system: prospects and challenges.Frontiers in cell and developmental biology · 2024Review
- Image analysis techniques for in vivo quantification of cerebrospinal fluid flow.Experiments in fluids · 2023Article
- Imaging glymphatic response to glioblastoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Cerebrospinal fluid solute transport associated with sensorimotor brain activity in rodents.Scientific reports · 2023Article
- Image Analysis Techniques for In Vivo Quantification of Cerebrospinal Fluid Flow.bioRxiv : the preprint server for biology · 2023Article
- Mechanically manipulating glymphatic transport by ultrasound combined with microbubbles.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 3 institutions in 3 countries.
Funding
Abstract
Despite the initial promise of immunotherapy for CNS disease, multiple recent clinical trials have failed. This may be due in part to characteristically low penetration of antibodies to cerebrospinal fluid (CSF) and brain parenchyma, resulting in poor target engagement. We here utilized transcranial macroscopic imaging to noninvasively evaluate in vivo delivery pathways of CSF fluorescent tracers. Tracers in CSF proved to be distributed through a brain-wide network of periarterial spaces, previously denoted as the glymphatic system. CSF tracer entry was enhanced approximately 3-fold by increasing plasma osmolality without disruption of the blood-brain barrier. Further, plasma hyperosmolality overrode the inhibition of glymphatic transport that characterizes the awake state and reversed glymphatic suppression in a mouse model of Alzheimer's disease. Plasma hyperosmolality enhanced the delivery of an amyloid-β (Aβ) antibody, obtaining a 5-fold increase in antibody binding to Aβ plaques. Thus, manipulation of glymphatic activity may represent a novel strategy for improving penetration of therapeutic antibodies to the CNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.